3.0.0 946 2023-01-15T23:33:07Z 2023-01-15T23:33:07Z Senate S S 2003-04-29 108 ssju00 Judiciary Committee Senate Standing Referred to 2003-04-29T21:34:09Z 2003-04-29 ssju00 Judiciary Committee Senate Read twice and referred to the Committee on the Judiciary. IntroReferral 2003-04-29 Sponsor introductory remarks on measure. (CR S5493-5494) IntroReferral B00100 9 Library of Congress 2003-04-29 Introduced in Senate IntroReferral 10000 9 Library of Congress L000174 Sen. Leahy, Patrick J. [D-VT] Patrick Leahy D VT N G000386 Sen. Grassley, Chuck [R-IA] Charles Grassley R IA E. 2003-04-29 True D000563 Sen. Durbin, Richard J. [D-IL] Richard Durbin D IL J. 2003-04-29 True F000061 Sen. Feingold, Russell D. [D-WI] RUSSELL FEINGOLD D WI D. 2003-04-29 True K000305 Sen. Kohl, Herb [D-WI] HERBERT KOHL D WI H. 2003-04-29 True S000148 Sen. Schumer, Charles E. [D-NY] Charles Schumer D NY E. 2003-04-29 True C000127 Sen. Cantwell, Maria [D-WA] Maria Cantwell D WA 2003-05-06 False Commerce Administrative procedure Antitrust law Civil Rights and Liberties, Minority Issues Civil actions and liability Drug approvals Drug industry Federal Trade Commission Fines (Penalties) Freedom of information Generic drugs Government Operations and Politics Government paperwork Health Independent regulatory commissions Injunctions Law Marketing Pharmaceutical research Research and development Restrictive trade practices Science, Technology, Communications Commerce 00 2003-04-29 Introduced in Senate 2006-11-28T17:35:40Z Exempts any such information or documentary material filed from disclosure under the Freedom of Information Act. Prohibits such information or material from being made public, except as relevant to any administrative or judicial action or proceeding.

Subjects an applicant or company to a civil penalty of up to $11,000 for each day such entity fails to comply with this Act, recoverable in a civil action brought by the United States or the FTC. Authorizes a U.S. district court to order compliance and grant equitable relief.]]>

Drug Competition Act of 2003 Display Title Drug Competition Act of 2003 Official Title as Introduced A bill to enhance competition for prescription drugs by increasing the ability of the Department of Justice and Federal Trade Commission to enforce existing antitrust laws regarding brand name drugs and generic drugs. Introduced in Senate IS Short Titles as Introduced Drug Competition Act of 2003 Introduced in Senate 2003-04-29T04:00:00Z 2003-04-29 Read twice and referred to the Committee on the Judiciary. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.